CBLI News Alert Cleveland Biolabs (CBLI) 0.28 12/25/2014 09:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cleveland Biolabs (CBLI) 0.28 $CBLI

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014
M2 - Thu Dec 11, 4:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/4psrtz/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Gamida Cell - Piramal Enterprises - Aeolus - Cleveland BioLabs - Soligenix - NeoStem - Pluristem - Cumberland - Cellerant - Humanetics - Meabco - ActoKine - Priaxon - ProCertus BioPharm - Angion Biomedica - Onconova - Avaxia Biologics - Bolder Biotechnology - Stemedica Cell Technologies - Biothera - Terapio - Neumedicines - RxBio For more information visit http://www.researchandmarkets.com/research/4psrtz/radiation
CBLI: 0.28 (+0.01)

Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer
ACCESSWIRE - Thu Nov 13, 9:50AM CST
WHITEFISH, MT / ACCESSWIRE / November 13, 2014 / The biotechnology industry has significantly outperformed the general market for some time now. So far this year, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has jumped nearly 30% compared to a nearly 10% return for the S&P 500 SPDR ETF (NYSE: SPY). Investors concerned about the industry's lofty valuation may want to take a look at some smaller diversified players in the space.
SPY: 207.77 (+0.02), AZN: 70.44 (+0.26), IBB: 299.80 (+5.12), CBLI: 0.28 (+0.01)

Cleveland BioLabs and Roswell Park Cancer Institute Announce Publication of Studies Demonstrating Curaxin CBL0137's Ability to Eradicate Drug-Resistant Cancer Stem Cells and Potentiate Efficacy of Gemcitabine in Preclinical Models of Pancreatic Cancer
Marketwired - Thu Nov 13, 9:22AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies in Oncotarget describing the preclinical efficacy of Curaxin CBL0137 as a single agent and in combination with the current standard-of-care therapy, gemcitabine, against different models of pancreatic ductal adenocarcinoma (PDA), including models of gemcitabine-resistant tumors. The reported studies were conducted by scientists at Roswell Park, SUNY Downstate Medical Center and Buffalo Biolabs, LLC.
CBLI: 0.28 (+0.01)

Cleveland BioLabs' (CBLI) CEO Yakov Kogan on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 2:10PM CST

CBLI: 0.28 (+0.01)

Cleveland BioLabs EPS of $0.07
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 6:13AM CST

CBLI: 0.28 (+0.01)

Cleveland BioLabs Reports Third Quarter 2014 Financial Results and Development Progress
Marketwired - Wed Nov 05, 6:00AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the third quarter ended September 30, 2014.
CBLI: 0.28 (+0.01)

Cleveland BioLabs to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Wednesday, November 5, 2014
ACCESSWIRE - Tue Nov 04, 4:09PM CST
BUFFALO, NY / ACCESSWIRE / November 4, 2014 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) will host a conference call and live webcast to discuss the results of the third quarter 2014, to be held Wednesday, November 5, 2014 at 10:00 AM Eastern Time.
CBLI: 0.28 (+0.01)

Cleveland BioLabs to Report Third Quarter 2014 Financial Results and Provide Operational Update on November 5
Marketwired - Tue Oct 28, 7:02AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on November 5, 2014, it will report its financial results for the third quarter ended September 30, 2014, and will host a conference call at 10:00 a.m. ET.
CBLI: 0.28 (+0.01)

HWCC, XOP, CBLI, RVBD, EXLS, CEP Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Tue Oct 07, 5:24AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Houston Wire & Cable Co (NASDAQ:HWCC), Canadian Overseas Petroleum Ltd (NYSE:XOP), Cleveland BioLabs Inc (NASDAQ:CBLI), Riverbed Technology Inc (NASDAQ:RVBD), EXLSERVICE HOLDINGS, INC. (NASDAQ:EXLS), Constellation Energy Partners LLC (NYSE:CEP) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
EXLS: 28.69 (+0.21), HWCC: 12.20 (-0.09), RVBD: 20.35 (+0.01), CEP: 3.35 (-0.06), XOP: 49.05 (-0.89), CBLI: 0.28 (+0.01)

Cleveland BioLabs Announces Approval to Start Phase 1 Study for Hematopoietic Stem Cell Mobilizer CBLB612 in Russian Federation
Marketwire - Mon Sep 15, 6:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced approval from the Ministry of Health of the Russian Federation to start a Phase 1 clinical trial with CBLB612, a drug in development for the induction and mobilization of hematopoietic stem cells (HSC).
CBLI: 0.28 (+0.01)

Global Bone Marrow Transplantation Therapeutics Pipeline Review 2014 - 7 Companies & 10 Drug Profiles
M2 - Fri Sep 12, 3:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxqmms/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - melphalan - Allogeneic MPC for Bone Marrow Transplantation - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Central Memory T Cell Therapy for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation For more information visit http://www.researchandmarkets.com/research/fx...one_marrow
PSTI: 2.46 (unch), CGEN: 8.58 (-0.17), SPPI: 6.90 (+0.15), CBLI: 0.28 (+0.01)

Cleveland BioLabs and Sabby Announce Resolution of Litigation
Marketwire - Mon Sep 08, 6:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Sabby Healthcare Volatility Master Fund, Ltd. and Sabby Volatility Warrant Master Fund, Ltd. (collectively, "Sabby" , today announced an agreement to resolve the pending claims against each other arising from the January 2014 sale of securities.
CBLI: 0.28 (+0.01)

CBLI, EDU, CLR, LL, CEVA, MSFG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 04, 9:58AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Cleveland BioLabs Inc (NASDAQ:CBLI), New Oriental Education & Technology Group Inc (NYSE:EDU), Continental Resources Inc (NYSE:CLR), Lumber Liquidators Holdings Inc (NYSE:LL), CEVA Inc (NASDAQ:CEVA), MainSource Financial Group Inc (NASDAQ:MSFG) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
CLR: 38.78 (-1.48), CEVA: 18.37 (+0.56), EDU: 20.35 (-0.04), LL: 63.91 (-0.41), CBLI: 0.28 (+0.01), MSFG: 20.38 (-0.01)

Cleveland BioLabs Announces Green Light to Submit Pre-Emergency Use Authorization Application for Entolimod
Marketwire - Wed Sep 03, 6:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the minutes from its meeting with the U.S. Food and Drug Administration (FDA) in July confirmed that the Company's existing efficacy and safety data and animal-to-human dose conversion are sufficient to proceed with a pre-Emergency Use Authorization (pre-EUA) submission for entolimod for reducing the risk of death following exposure to potentially lethal irradiation occurring as the result of a radiation disaster.
CBLI: 0.28 (+0.01)

Cleveland BioLabs to Report Outcome of July FDA Meeting and Host Conference Call on September 3
Marketwire - Tue Sep 02, 3:30PM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on September 3, 2014, it will report the outcome of the Company's July meeting with the U.S. Food and Drug Administration (FDA), and will host a conference call at 11:00 a.m. ET.
CBLI: 0.28 (+0.01)

Cleveland BioLabs to Present at Rodman & Renshaw 16th Annual Global Investment Conference
Marketwire - Tue Sep 02, 8:02AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the Rodman & Renshaw 16th Annual Global Investment Conference, September 8-10, in New York, NY.
CBLI: 0.28 (+0.01)

Cleveland BioLabs Reports Second Quarter 2014 Financial Results and Development Progress
Marketwire - Thu Aug 07, 6:01AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the second quarter ended June 30, 2014.
CBLI: 0.28 (+0.01)

Cleveland BioLabs to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Thursday, August 7, 2014
ACCESSWIRE - Wed Aug 06, 3:49PM CDT
BUFFALO, NY / ACCESSWIRE / August 6, 2014 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Thursday, August 7, 2014 at 10:00 AM Eastern Time.
CBLI: 0.28 (+0.01)

Cleveland BioLabs to Report Second Quarter 2014 Financial Results and Provide Operational Update on August 7
Marketwire - Tue Jul 29, 7:00AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on August 7, 2014, it will report its financial results for the second quarter ended June 30, 2014, and will host a conference call at 10:00 a.m. ET.
CBLI: 0.28 (+0.01)

Cleveland BioLabs Reduces Debt With $3.5 Million At-the-Market Private Placement of Unregistered Stock
Marketwire - Wed Jun 18, 8:25AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that it entered into a securities purchase agreement (the "Purchase Agreement" with Dr. Mikhail Mogutov, Chairman of the Board of Directors of Incuron, LLC and Chairman of the Investment Committee and founder of Bioprocess Capital Ventures and one institutional investor (the "Investors" , to issue and sell in a private placement $3.5 million worth of the Company's common stock, par value $.005 per share (the "Common Stock" , and warrants to purchase Common Stock.
CBLI: 0.28 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
Chicago Kertész Show Puts Photography's Quiet Giant First

Updated Category News Views 112

A fork, a plate, and a sharp eye can outlast plenty of louder art. Leica Gallery Chicago is putting that proposition on the wall with André Kertész: The Master, opening December 4, 2026 and running through January 17, 2027. More than thirty signature works is not a sprawling museum survey, and frankly that may be the point. Kertész did not need grand scale to make his...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 139

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
Duetti, CesiumAstro, and a Busy NYSE Capital Morning

Updated Category News Views 94

Three very different piles of money are jamming up the November 20 NYSE slate, and that contrast is the whole point. Private music catalogs, space-and-defense communications, and a new stock-and-bond ETF do not belong in the same bucket. Yet all three are competing for investor attention before the opening bell, alongside Danaos Corporation's 20th listing anniversary....

Continue Reading
AMP Pushes Debt Wall to 2029 With €1.3B Green Notes

Updated Category News Views 108

A Refinancing With Some Actual Breathing Room Metal cans may be boring, but a debt wall arriving in 2028 is not—and Ardagh Metal Packaging has moved that problem down the road. AMP priced €1.3 billion of senior secured floating-rate green notes on November 20, 2026. The proceeds are earmarked to redeem $600 million of senior secured green notes due in 2028 and €450...

Continue Reading
Teachstone’s Bronze Award Puts Classroom Quality in Focus

Updated Category News Views 36

Small Classroom Moments Finally Get Their Due A child’s hesitant question can disappear in the noise of a busy classroom, which is precisely why Teachstone’s latest recognition deserves more than the usual polite golf clap. The Charlottesville-based Certified B Corporation received a Bronze Anthem Award for its “From Measurement to Momentum” initiative, in the...

Continue Reading
Shenzhen’s 50-Year Message Carries Real Trade Weight

Updated Category News Views 68

A city once framed as a frontier fishing village is being presented as China’s sharpest recent economic before-and-after picture. At the welcome dinner for the 33rd APEC Economic Leaders’ Meeting in Shenzhen, President Xi Jinping gave guests a compact geographic guide to China’s past: Xi’an for thousands of years, Beijing for 500 years, Shanghai for 100 years, and...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
Sprocket’s GigaOm Leap Puts PTaaS Claims Under Scrutiny

Updated Category News Views 65

Security vendors love a shiny quadrant, but this one deserves more than the usual polite golf clap. Sprocket Security moved from Challenger and Outperformer in GigaOm’s 2025 Penetration Testing as a Service assessment to a Leader in the version 5 report released in 2026. That is a meaningful jump in a category where buyers are tired of annual testing reports that go...

Continue Reading

Top 5 Most Recently Viewed Articles

Aluminum Design Fumble: Geometry Over Wall Thickness

Updated Category News Views 420

A Misstep in Aluminum Design Practices Well, here's a nugget of wisdom for the metal enthusiasts out there—stop beefing up aluminum components with thicker walls and focus on smart geometry. This isn't a drill, folks. Mark Coyle, a seasoned mind over at American Custom Metals, has been waving the flag for smarter aluminum design methods right from Rochester, NY, and...

Continue Reading
BW LPG Limited Welcomes BW Chinook: A Significant Milestone

Updated Category News Views 180

Significant Acquisition by BW LPG Limited BW LPG Limited has recently taken a remarkable step in enhancing its fleet and operational capabilities. The company announced the acquisition of the vessel BW Chinook, marking an important milestone in its ongoing strategy to strengthen its position in the global LPG market. Details of the Vessel Delivery Following a stock...

Continue Reading
COMAC's Expansion: New Hong Kong Office and Maintenance Deal

Updated Category News Views 175

COMAC's Global Expansion Efforts Chinese planemaker COMAC has taken a significant step in its quest to enter the global passenger jet market by inaugurating its second international office in Hong Kong. This move aligns with their strategy to provide enhanced services and establish a stronger footprint outside mainland China. The opening not only symbolizes growth but...

Continue Reading
Torrid Holdings CEO Lisa Harper Makes Strategic Stock Move

Updated Category News Views 415

Lisa Harper's Recent Sale of Company Shares Lisa Harper, the CEO of Torrid Holdings Inc. (NYSE: CURV), has recently sold shares worth $283,909, according to a filing with the Securities and Exchange Commission. In this transaction, she sold 74,713 shares at a price of $3.80 each. This sale is part of her exercise of the underwriters' option to purchase additional shares...

Continue Reading
Getty Images Plans Q3 2024 Financial Results Release Date

Updated Category News Views 102

Getty Images Announces Q3 2024 Financial Results Date Getty Images Holdings, Inc. (NYSE: GETY), a leader in the global visual content industry, is gearing up to share its financial results for the third quarter of 2024. The results will be unveiled right after market closing on November 7, 2024. This announcement signals an important moment for stakeholders keeping a...

Continue Reading